N/A N=212 Intrapartum Maternal Oxygen Supplementation: Effects on the Mother and Neonate
Intrauterine Resuscitation
Primary: Umbilical Artery Malondialdehyde — 9.8; 10.2 umol/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=201 Risk of Oxygen During Cardiac Surgery Trial
Cardiac Surgery
Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml
Phase 3 N=738 Long-term Oxygen Treatment Trial
Chronic Obstructive Pulmonary Disease
Primary: Death or Hospitalization, Whichever Occurs First — 34.2; 36.4 Composite events/100 person-years — p=0.52
Phase 4 N=33 Neuroimaging During Pure Oxygen Breathing
Hyperoxia · Hypoxia, Brain · Neurobehavioral Manifestations
Primary: Cerebral Blood Flow — 48.54; 36.17 ml/min/100g tissue — p=<0.05
Phase 1 N=16 Reoxygenation After Cardiac Arrest II (REOX II Study)
Cardiac Arrest
Primary: Plasma Isofurans (pg/mL)/Isoprostanes (pg/mL) Ratio
N/A N=60 Effect of Super-Oxygenated Water on Blood Oxygen Saturation
Adult Subject
Primary: SpO2 Response Rate — 21; 11 Participants — p=0.010
N/A N=20 Susceptibility of Cardiorespiratory Responses to Ozone During Cycling Exercise
Ozone Exposure During Rest and Exercise
Primary: Time-to-exhaustion on Maximal Cycling Bout — 209; 235 seconds — p=0.092
Phase 2 N=19 High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients
Cancer
Primary: Change in Dyspnea Numeric Score Between 0 and 10 Minutes — -1.8; -1.8; -0.6; -0.5 score on a scale
Phase 2 N=20 Hyperbaric Oxygen Therapy for Lung Transplantation
Disorder Related to Lung Transplantation · Central Airway Stenosis · Airway Exudative Plaques
Primary: Subjects Needing Airway Stent Placement as Determined by Transbronchial Lung Biopsy. — 4; 4 Participants — p=1
N/A N=29 Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period
Hypoplastic Left Heart Syndrome · Total Anomalous Pulmonary Venous Return · Truncus Arteriosus
Primary: Systemic Oxidative Stress Based on Thiobarbituric Acid Reactive Substances (TBARS) — 1.21; 1.93; 1.09; 1.77 Fold Change from Baseline — p=<0.01
N/A N=86 Pulmonary Function After Hyperbaric Oxygen Therapy
Oxygen Toxicity
Primary: Change in Percentage Predicted Forced Expiratory Volume in One Second (FEV1%) — 88.0; 85.9; 87.4; 84.6 Percentage of FEV1
N/A N=91 Oxygen Therapy for the Treatment of Undifferentiated Headache in the Emergency Department
Headache
Primary: Time to Relief (Min) — 92.2; 83.9; 35.4 Minutes
N/A N=1,301 Pragmatic Trial Examining Oxygenation Prior to Intubation
Acute Respiratory Failure
Primary: Incidence of Hypoxemia — 57; 118 Participants
N/A N=114,921 Oxygen Therapy Use in Patients With Fibrotic Interstitial Lung Disease
Lung Diseases, Interstitial
Primary: Time to Oxygen Therapy Initiation — 27.5; NA Months
Phase 2 N=96 Normobaric Hyperoxia for Intracerebral Hemorrhage
Normobaric Hyperoxia · Intracerebral Hemorrhage
Primary: Percentage of Patients With mRS 0-3 — 39; 27 Participants
N/A N=31 Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation
Respiratory Distress Syndrome in Premature Infants · Very Low Birth Weight Baby
Primary: Maximum Factional Inspired Oxygen Percent (FiO2) — 48; 39 percentage of Inspired Oxygen — p=0.0012
N/A N=12 Acute Intermittent Hypoxia in Traumatic Brain Injury
Brain Injuries, Traumatic
Primary: Change in Vitals at Visit 2 — 0 Participants
Phase 3 N=100 Does High Intraoperative Inspired Oxygen Reduce Postoperative Arterial Oxygen Saturation?
Atelectasis
Primary: Oxygen Requirement to Maintain SpO2>90% — 1; 1; 1; 1 liters per minute
Phase 2 N=18 Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability of Drug, Assessed by Change in Methemoglobin Levels — 0.4; 0.5; 0.3; 0.3 Percent of Methemoglobin Level
N/A N=572 Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients
Trauma · Critical Illness · Oxygen Toxicity
Primary: Patient-time Hyperoxic and Not on Room Air — 40.6; 33.9 Percent patient-time in hyperoxia — p=0.03
N/A N=30 Comparison of Oxygen Delivery Devices for Reversal of Altitude-Induced Hypoxemia in Normal Subjects
Hypoxemia · Hypobaric Hypoxemia
Primary: Return of Oxygen Saturation to Baseline (Sea Level) Values — 6; 8; 10; 4 participants — p=0.3
N/A N=50 Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function
Abnormality, Respiratory System · Autonomic Nervous System
Primary: FEV1 — 0.94; 1.08; 0.95; 1.09 percentage of predicted normal values
N/A N=62 Air Pollution Study: The Effect of Ozone on the Lung
Air Pollution
Primary: Concentrations of M1 and M2 Macrophages in the Sputum 24 Hours After Exposure. — 6.823; 1.367 ratio of M2 to M1 macrophages
N/A N=114 Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings
Electronic Fetal Monitoring · Fetal Hypoxia · Fetal-Placental Circulation
Primary: Mean Umbilical Artery Lactate at Delivery — 3.5; 3.4 mmol/L — p=0.69
Phase 2 N=44 Normobaric Oxygen (NBO) Therapy in Acute Migraine
Migraine
Primary: Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS) — 1.38; 1.22 units on a scale — p=0.674
N/A N=34 Preoxygenation With Optiflow™ - the Effect of Speech on Lung Oxygenation.
Unrecognized Condition
Primary: End Tidal Oxygen Fraction — 43.9; 81.9 percentage of End-Tidal Oxygen Fraction
N/A N=2,541 Pragmatic Investigation of optimaL Oxygen Targets Trial
Respiratory Failure
Primary: Ventilator-free Days (VFDs) to Study Day 28 — 20; 21; 21 number of days
N/A N=19 Supplemental Oxygen in Pulmonary Fibrosis
Pulmonary Fibrosis
Primary: Change in University of California San Diego Shortness of Breath Questionnaire From Immediately Prior to One Month After Starting Daily-use Supplemental Oxygen — 0.9…
N/A N=20 Evaluation of the Delivery of Optimized Supersaturated Oxygen Therapy to Treat Patients With an Acute Heart Attack
Anterior Wall Acute Myocardial Infarction
Primary: The Feasibility of Intracoronary Infusion of SSO2 Therapy — 20 participants
N/A N=29 Oxygen Reserve Index (ORi) Expanded Data Set Validation of INVSENSOR00029
Healthy
Primary: Concordance for Changes in ORi Values as Compared to Corresponding Changes in PaO2 Values — 99.4; 89.74; 89.86 percentage of accuracy